Stereotactic body radiotherapy in the management of oligometastatic and recurrent biliary tract cancer: single-institution analysis of outcome and toxicity.
Ciro FranzeseMarco Lorenzo BonuTiziana ComitoElena ClericiMauro LoiPierina NavarriaDavide FranceschiniTiziana PressianiLorenza RimassaMarta ScorsettiPublished in: Journal of cancer research and clinical oncology (2020)
Stereotactic body radiotherapy (SBRT) is feasible in the context of mBTC. OS and PFS results are promising, considering that our patients were heavily pre-treated with systemic therapy. Patients with nodal or lung relapse have better prognosis. Distant relapses remain the main pattern of failure, but treatment of all metastatic sites seems to improve DMFS.
Keyphrases
- radiation therapy
- end stage renal disease
- early stage
- newly diagnosed
- locally advanced
- ejection fraction
- chronic kidney disease
- lymph node
- squamous cell carcinoma
- small cell lung cancer
- papillary thyroid
- prognostic factors
- peritoneal dialysis
- neoadjuvant chemotherapy
- cell therapy
- bone marrow
- young adults
- free survival
- smoking cessation